Pagès Franck, Taieb Julien, Laurent-Puig Pierre, Galon Jérôme
Laboratory of Integrative Cancer Immunology, INSERM, Paris, France.
Equipe Labellisée Ligue Contre le Cancer, Paris, France.
Oncoimmunology. 2020 Aug 28;9(1):1812221. doi: 10.1080/2162402X.2020.1812221.
The consensus Immunoscore has a prognostic value that has been confirmed in two randomized phase 3 clinical trials, and it provides a reliable estimate of the recurrence risk in colon cancer. The latest edition of the WHO classification of the Digestive System Tumors introduced for the first time the immune response as an essential and desirable diagnostic criteria for digestive cancers. Therefore, the immune response and Immunoscore evaluation within the tumor microenvironment is clinically relevant. In addition, the evaluation of the Immunoscore in stage III colon cancer patients from the IDEA France clinical trial evaluating 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy demonstrated the predictive value of Immunoscore for treatment duration. Immunoscore predicted response to 6 months FOLFOX chemotherapy both in low- and high-risk Stage III patients. Low-risk patients (T, N) with High-Immunoscore had the 3-year DFS of 91.4% when treated with the 6-month FOLFOX, and only 80.8% with the 3-month regimen. The international validation of the prognostic value of the consensus Immunoscore together with its predictive value to guide treatment provides important information for the personalized management of colon cancer patients.
共识免疫评分具有预后价值，这已在两项随机3期临床试验中得到证实，并且它能对结肠癌的复发风险提供可靠估计。世界卫生组织消化系统肿瘤分类的最新版本首次将免疫反应作为消化系统癌症的一项基本且理想的诊断标准。因此，肿瘤微环境中的免疫反应和免疫评分评估具有临床相关性。此外，在法国IDEA临床试验中，对III期结肠癌患者进行免疫评分评估，该试验比较了3个月与6个月的奥沙利铂辅助化疗，结果证明免疫评分对治疗时长具有预测价值。免疫评分在低风险和高风险III期患者中均能预测对6个月FOLFOX化疗的反应。高免疫评分的低风险患者（T，N）接受6个月FOLFOX治疗时3年无病生存率为91.4%，而接受3个月治疗方案时仅为80.8%。共识免疫评分的预后价值及其指导治疗的预测价值的国际验证为结肠癌患者的个性化管理提供了重要信息。
